Literature DB >> 14650966

[Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study].

Toshiaki Tanaka1, Susumu Sueyoshi, Hiroko Sasahara, Satoru Matono, Hideaki Yamana, Kazuo Shirouzu, Hiromasa Fujita.   

Abstract

A pilot study has been conducted since January 2002 to investigate whether chemotherapy with docetaxel, 5-FU, CDDP could be an effective regimen for recurrent esophageal cancer. Ten patients with recurrent esophageal cancer were treated with the combination of docetaxel 60 mg/m2 (day 1), CDDP 10 mg/body (days 1-5) and 5-FU 500 mg/body (days 1-5) at intervals of 2-3 weeks. All patients had undergone surgery, had a recurrent tumor and had already been treated with chemo-radiotherapy or chemotherapy with CDDP + 5-FU. Response evaluation in 10 patients with measurable disease: partial response 4 patients, stable disease 2 patients and progressive disease 4 patients. The main NCI-CT grade 3/4 toxicity was leukopenia (8/10). Mild to moderate nausea (> or = grade 2) occurred in 3/10 patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14650966

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP.

Authors:  Junichi Seike; Toru Sawada; Naoya Kawakita; Yota Yamamoto; Yasuhiro Yuasa; Hiromichi Yamai; Hirokazu Takachi; Takahiro Yoshida; Akira Tangoku
Journal:  Int J Surg Oncol       Date:  2011-08-17

2.  Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer.

Authors:  V Chiarion-Sileni; L Corti; A Ruol; R Innocente; C Boso; P Del Bianco; J Pigozzo; R Mazzarotto; O Tomassi; E Ancona
Journal:  Br J Cancer       Date:  2007-01-23       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.